Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

被引：60
|
作者：
Lavery, Amy M. [1 ]
Verhey, Leonard H. [2 ]
Waldman, Amy T. [1 ,3 ,4 ]
机构：
[1] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA
[2] Univ Toronto, Hosp Sick Children, Program Neurosci & Mental Hlth, Pediat Demyelinating Dis Program, Toronto, ON M5G 1X8, Canada
[3] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
来源：
MULTIPLE SCLEROSIS INTERNATIONAL | 2014年 / 2014卷
关键词：
D O I：
10.1155/2014/262350
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as acute relapses and progressive disability. As a primary endpoint for clinical trials in MS, disability is difficult to both characterize and measure. Furthermore, the recovery from relapses and the rate of disability vary considerably among patients. Given these challenges, investigators have developed and studied the performance of various outcome measures and surrogate endpoints in MS clinical trials. This review defines the outcome measures and surrogate endpoints used to date in MS clinical trials and presents challenges in the design of both adult and pediatric trials.
引用
收藏
页数：13
相关论文
共 50 条
  • [41] Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis
    Jung, P.
    Beyerle, A.
    Ziemann, U.
    [J]. MULTIPLE SCLEROSIS, 2008, 14 (04): : 553 - 556
  • [42] Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
    Migliore, S.
    Ghazaryan, A.
    Simonelli, I.
    Pasqualetti, P.
    Squitieri, F.
    Curcio, G.
    Landi, D.
    Palmieri, M. G.
    Moffa, F.
    Filippi, M. M.
    Vernieri, F.
    [J]. BEHAVIOURAL NEUROLOGY, 2017, 2017
  • [43] Clinical predictors of disability in treatment-naive relapsing-remitting multiple sclerosis patients
    Ivaniuk, A.
    Solodovnikova, I.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 921 - 921
  • [44] Cognitive impairment predicts disability and progression in newly-diagnosed relapsing-remitting multiple sclerosis
    Moccia, M.
    Lanzillo, R.
    Palladino, R.
    Costabile, T.
    Russo, C. V.
    De Rosa, A.
    Carotenuto, A.
    Maniscalco, G. T.
    Morra, V. Brescia
    Chang, K. C. -M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 87 - 87
  • [45] Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis
    Strijbis, Eva M.
    Coerver, Eline
    Mostert, Jop
    van Kempen, Zoe L. E.
    Killestein, Joep
    Comtois, Jacynthe
    Repovic, Pavle
    Bowen, James D.
    Cutter, Gary
    Koch, Marcus
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (10): : 792 - 799
  • [46] Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study
    Lorscheider, J.
    Benkert, P.
    Schadelin, S.
    Yaldizli, O.
    Derfuss, T.
    Lalive, P.
    Pot, C.
    Mueller, S.
    Vehoff, J.
    Sinnecker, T.
    Wurfel, J.
    Achtnichts, L.
    Findling, O.
    Nedeltchev, K.
    Du Pasquier, R.
    Disanto, G.
    Zecca, C.
    Kamm, C.
    Salmen, A.
    Chan, A.
    Granziera, C.
    Gobbi, C.
    Kappos, L.
    Kuhle, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 102 - 103
  • [47] What's in a name? The impact of definition and durability in clinical trial outcome measures in relapsing-remitting multiple sclerosis
    Satyanarayan, S.
    Cutter, G.
    Krieger, S.
    Cofield, S.
    Wolinsky, J.
    Lublin, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 263 - 264
  • [48] A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics
    Solomon, Andrew J.
    Bernat, James L.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 109 - 112
  • [49] Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis
    Greenberg, Benjamin M.
    Balcer, Laura
    Calabresi, Peter A.
    Cree, Bruce
    Cross, Anne
    Frohman, Teresa
    Gold, Ralf
    Havrdova, Eva
    Hemmer, Bernhard
    Kieseier, Bernd C.
    Lisak, Robert
    Miller, Aaron
    Racke, Michael K.
    Steinman, Lawrence
    Stuve, Olaf
    Wiendl, Heinz
    Frohman, Elliot
    [J]. JAMA NEUROLOGY, 2013, 70 (02) : 248 - 251
  • [50] The impact of long-term treatment with disease modifying therapy on disability progression in relapsing-remitting multiple sclerosis patients
    Carra, Adriana J.
    Onaha, Patricia S.
    Sinay, Vladimiro
    Halfon, Mario J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S36 - S36
12345